Rhumbline Advisers Has $32.46 Million Stock Position in Baxter International Inc. (NYSE:BAX)

Rhumbline Advisers increased its stake in Baxter International Inc. (NYSE:BAX - Free Report) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,113,125 shares of the medical instruments supplier's stock after purchasing an additional 13,424 shares during the quarter. Rhumbline Advisers owned about 0.22% of Baxter International worth $32,459,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of BAX. CKW Financial Group raised its position in shares of Baxter International by 19.3% during the 4th quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier's stock worth $77,000 after buying an additional 425 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Baxter International by 23.2% in the third quarter. Farther Finance Advisors LLC now owns 2,519 shares of the medical instruments supplier's stock valued at $96,000 after acquiring an additional 475 shares in the last quarter. LRI Investments LLC increased its stake in shares of Baxter International by 60.8% during the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier's stock valued at $59,000 after acquiring an additional 590 shares during the period. Greenleaf Trust raised its holdings in Baxter International by 10.0% during the third quarter. Greenleaf Trust now owns 9,491 shares of the medical instruments supplier's stock worth $360,000 after purchasing an additional 859 shares in the last quarter. Finally, Fortitude Family Office LLC acquired a new stake in Baxter International in the third quarter worth approximately $38,000. Institutional investors and hedge funds own 90.19% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on BAX shares. Stifel Nicolaus dropped their price objective on Baxter International from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Monday, November 11th. Citigroup reduced their price objective on shares of Baxter International from $37.00 to $35.00 and set a "neutral" rating for the company in a research report on Wednesday, December 11th. JPMorgan Chase & Co. dropped their target price on shares of Baxter International from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Friday. StockNews.com cut shares of Baxter International from a "buy" rating to a "hold" rating in a report on Monday, November 11th. Finally, Barclays assumed coverage on Baxter International in a report on Thursday. They issued an "overweight" rating and a $39.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Baxter International has an average rating of "Hold" and an average target price of $38.80.

Baxter International Trading Up 1.3 %

Shares of BAX stock traded up $0.43 during trading hours on Friday, reaching $33.87. 7,264,381 shares of the stock traded hands, compared to its average volume of 4,927,193. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $17.29 billion, a PE ratio of 169.33, a PEG ratio of 9.83 and a beta of 0.61. Baxter International Inc. has a 1-year low of $28.33 and a 1-year high of $44.01. The business has a fifty day moving average price of $30.57 and a 200 day moving average price of $34.14.

Baxter International (NYSE:BAX - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.06. The company had revenue of $2.75 billion for the quarter, compared to the consensus estimate of $2.67 billion. Baxter International had a net margin of 0.77% and a return on equity of 18.30%. On average, equities research analysts forecast that Baxter International Inc. will post 1.83 EPS for the current year.

Baxter International Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 2.01%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International's dividend payout ratio is currently 340.02%.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.